COMP <GO>
HIMS vs LLY // FORWARD P/E MULTIPLE
Hims & Hers Health Inc. (NYSE) VS. Eli Lilly and Company (NYSE) • 15-METRIC TALLY: HIMS 3
— LLY 11
▲ FORWARD P/E MULTIPLE LEADER: LLY
LAST: $29.67 (+1.19%) • MKT CAP: $6.92B
forward-pe
45.3x
LAST: $1,373.70 (+6.63%) • MKT CAP: $1.29T
forward-pe
26.3x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (HIMS VS. LLY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | HIMS | LLY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 73.80% | 83.64% | -9.84 | LLY | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 8.40% | 32.36% | -23.96 | LLY | /roic <GO> |
| EV/EBITDA & P/E Valuation | 37.7x | 36.4x | +1.28 | LLY | /valuation <GO> |
| Free Cash Flow Yield | 2.81% | 2.30% | +0.51 | HIMS | /fcf-yield <GO> |
| Operating Margin | 4.50% | 40.21% | -35.71 | LLY | /operating-margins <GO> |
| Net Profit Margin | 5.50% | 31.90% | -26.40 | LLY | /net-margins <GO> |
| Revenue Growth (YoY) | 59.00% | 45.51% | +13.49 | HIMS | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.49% | -0.49 | LLY | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.95 | 9.29 | -5.34 | LLY | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 9/9 | -1.00 | LLY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 6.77% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 53.1 | 66.6 | -13.50 | LLY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.05 | 0.51 | +0.54 | HIMS | /macro-sensitivity <GO> |
| Forward P/E Multiple ACTIVE | 45.3x | 26.3x | +19.05 | LLY | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $6.92B | $1.29T | -$1.29T | LLY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | HIMS REV | LLY REV | HIMS GROSS % | LLY GROSS % | HIMS FCF | LLY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $2.35B | $65.18B | 73.8% | 83.0% | $194.4M | $16.81B |
| FY 2024 | $1.48B | $45.04B | 79.5% | 81.3% | $184.6M | $8.82B |
| FY 2023 | $872.0M | $34.12B | — | 79.3% | $34.2M | $4.24B |
| FY 2022 | — | $28.54B | — | 76.8% | — | $7.59B |
| FY 2021 | — | $28.32B | — | 74.2% | — | $7.37B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
HIMS // BETA 1.05
LLY // BETA 0.51